Search research articles
Contact Us
Filters
Showing results (201-210 of 578) with videos related to
Page
of 58
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study
Ignace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
Future Oncology (London, England)
|
February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
Journal of Ovarian Research
|
May 30, 2014
Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium
Elena Ioana Braicu, Toon Van Gorp, Mani Nassir, et al.
Physical Therapy
|
January 14, 2014
Lymphoedema Functioning, Disability and Health Questionnaire for Lower Limb Lymphoedema (Lymph-ICF-LL): reliability and validity
Nele Devoogdt, An De Groef, Ad Hendrickx, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2012
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
Karina Dahl Steffensen, Marianne Waldstrøm, Niels Pallisgård, et al.
Gynecologic Oncology
|
December 22, 2014
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Ursula Matulonis, Ignace Vergote, Floor Backes, et al.
Gynecologic Oncology
|
July 24, 2019
Joint ENGOT and GOG Foundation requirements for trials with industry partners
Ignace Vergote, Robert L Coleman, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 20, 2019
Joint ENGOT and GOG Foundation requirements for trials with industry partners
Ignace Vergote, Robert L Coleman, Sandro Pignata, et al.
BMC Cancer
|
January 24, 2008
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation
Olivier Gevaert, Frank De Smet, Toon Van Gorp, et al.
Archives of Gynecology and Obstetrics
|
May 30, 2020
Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis
Stamatios Petousis, Panagiotis Christidis, Chrysoula Margioula-Siarkou, et al.
Page
of 58
Search research articles
Search
Showing results (201-210 of 578) with videos related to
Sort By:
Page
of 58
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study
Ignace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
Future Oncology (London, England)
|
February 10, 2018
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Kathleen N Moore, Ignace Vergote, Ana Oaknin, et al.
Journal of Ovarian Research
|
May 30, 2014
Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium
Elena Ioana Braicu, Toon Van Gorp, Mani Nassir, et al.
Physical Therapy
|
January 14, 2014
Lymphoedema Functioning, Disability and Health Questionnaire for Lower Limb Lymphoedema (Lymph-ICF-LL): reliability and validity
Nele Devoogdt, An De Groef, Ad Hendrickx, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2012
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
Karina Dahl Steffensen, Marianne Waldstrøm, Niels Pallisgård, et al.
Gynecologic Oncology
|
December 22, 2014
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Ursula Matulonis, Ignace Vergote, Floor Backes, et al.
Gynecologic Oncology
|
July 24, 2019
Joint ENGOT and GOG Foundation requirements for trials with industry partners
Ignace Vergote, Robert L Coleman, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 20, 2019
Joint ENGOT and GOG Foundation requirements for trials with industry partners
Ignace Vergote, Robert L Coleman, Sandro Pignata, et al.
BMC Cancer
|
January 24, 2008
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation
Olivier Gevaert, Frank De Smet, Toon Van Gorp, et al.
Archives of Gynecology and Obstetrics
|
May 30, 2020
Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis
Stamatios Petousis, Panagiotis Christidis, Chrysoula Margioula-Siarkou, et al.
Page
of 58